{"url_path":"/sec/vvos/8-k/2026-06-25/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","accession_number":"0001493152-26-030190","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":119,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 22, 2026, the Company issued a press release announcing the Letter Agreement described in Item 1.01 above. A\ncopy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe\ninformation furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section\n18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that\nsection, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange\nAct, except as expressly set forth by specific reference in such a filing."}